In the first half of this two-part episode, Dr. Kelly Gwathmey, MD, and Dr. Pushpa Narayanaswami, MD, FAAN, first discuss the evolving landscape of generalized myasthenia gravis (gMG) treatment, including the foundational role of conventional immunotherapies and the emergence of novel agents like FcRn receptor antagonists and complement inhibitors. Learn about the mechanisms, clinical trial data, and practical considerations for integrating these therapies into patient care.

To access the other episodes in the gMG disease dialogues series and earn CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/advances-gmg-disease-dialogues-series/. The series features expert discussion on the new and emerging therapies for gMG, practical insights for integrating treatment advances, and the importance of multidisciplinary collaboration to optimize patient care.

Earn free CME credits- visit https://myastheniagravis.ime.springerhealthcare.com/ to check out the complete accredited program on optimizing patient outcomes in gMG.

Intended for healthcare professionals only.

Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.

© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.

In this episode Prof. Amer Zeidan, MBBS, MHS, and Prof. Courtney D. DiNardo,MD, MSCE, discuss mechanisms of action, efficacy, and safety profiles of novel targeted therapies for IDH1-mutant relapsed/refractory acute myeloid leukemia (R/R AML​).

To access the video-based podcast episode, and learn more about the full series on molecular testing and targeted treatments for improved patient outcomes in R/R AML, visit https://springermedicine.com/aml-expert-series-overview/50892434

Intended for healthcare professionals only.

Supported by an independent educational grant from Rigel.

© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.

In this first episode of the “gMG disease dialogues” series, host Dr. Kelly Gwathmey, MD, and guest speaker Dr. Sithara Ramdas, MD, discuss adult and pediatric generalized myasthenia gravis (gMG), specifically:

To access the other episodes in the gMG disease dialogues series and earn CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/advances-gmg-disease-dialogues-series/. The series features expert discussion on the new and emerging therapies for gMG, practical insights for integrating treatment advances, and the importance of multidisciplinary collaboration to optimize patient care.

Earn free CME credits- visit https://myastheniagravis.ime.springerhealthcare.com/ to check out the complete accredited program on optimizing patient outcomes in gMG.

Intended for healthcare professionals only.

Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.

© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.

In this patient-physician conversation, Janel Worcester-Brown and Dr. Kelly Gwathmey, MD, engage in compelling and candid discussion of the realities of living with generalized myasthenia gravis (gMG) and the challenges patients face navigating their healthcare journey.

Together, they reveal real-world patient perspectives combined with expert provider insights, to uncover the lived experiences of patients with generalized myasthenia gravis (gMG), the unmet needs and gaps in care, and how embracing a patient-centric approach and shared decision-making can make a difference.

To access the interactive video-based module and learn more about the full, free accredited program on optimizing patient outcomes in gMG, and claim CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/

Intended for healthcare professionals only.

Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.

© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.

In this episode Prof. Amer Zeidan, MBBS, MHS, and Dr. Eunice Wang, MD, discuss:

To access the video-based podcast episode, and learn more about the full series on molecular testing and targeted treatments for improved patient outcomes in R/R AML, visit https://springermedicine.com/aml-expert-series-overview/50892434

Intended for healthcare professionals only.

Supported by an independent educational grant from Rigel.

© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.

In this episode Prof. Amer Zeidan, MBBS, MHS, and Dr. Sanam Loghavi, MD, discuss:

To access the video-based podcast episode, and learn more about the full series on molecular testing and targeted treatments for improved patient outcomes in R/R AML, visit https://springermedicine.com/aml-expert-series-overview/50892434

Intended for healthcare professionals only.

Supported by an independent educational grant from Rigel.

Supported by an independent educational grant from Rigel.

In this episode, Dr. Jennifer Green discusses key continuous glucose monitoring (CGM) updates to the 2025 American Diabetes Association (ADA) Standards of Care in Diabetes.

This material is made possible thanks to an independent educational grant from Abbott. Intended for healthcare professionals only.

This episode is part of the Independent Medical Education program entitled, 'T2D & CKD: Putting evidence into practice'. This independent medical educational program will support the multidisciplinary team (MDT) to proactively identify and manage patients with CKD and T2D whilst incorporating the latest clinical guidelines. In a series of vodcasts, our expert faculty will explain best practices for the identification, classification and management of CKD in T2D, drawing on recent advances in therapies and insights from a patient with these comorbidities.

To learn more about the full program, visit https://ckd-t2d.ime.springerhealthcare.com/

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change. This educational activity is intended for an international audience of non-US and non-UK HCPs.

This program is supported by an educational grant from Novo Nordisk A/S.

As part of our independent medical education program, featuring conference coverage in the rapidly progressing field of Alzheimer's Disease, we bring you the latest news and updates from the major neurology congresses throughout 2024.

Direct from CTAD 2024 Claire Paquet presents this episode on the implications of real-world and recommendation data on anti-amyloid antibody therapies for Alzheimer's disease.

This activity is supported by an educational grant from Lilly.---

As part of our independent medical education program, featuring conference coverage in the rapidly progressing field of Alzheimer's Disease, we bring you the latest news and updates from the major neurology congresses throughout 2024.

Direct from CTAD 2024 this episode features Juan Fortea who discusses future opportunities for anti-amyloid antibody treatment in view of real-world clinical trial data.

This activity is supported by an educational grant from Lilly.---